{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-047925","form_type":"8-K/A","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.385351+00:00","generated_at":"2026-06-10T19:17:37.613421+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Graphite Bio amends CEO Josh Lehrer's separation agreement with consulting and equity acceleration terms","bullets":["Separation agreement dated Sept 7, 2023 provides Tier 1 severance benefits under Executive Severance Plan.","Lehrer to serve as consultant for up to 12 months or until a Strategic Transaction closes.","Equity awards continue vesting during consulting; acceleration if Strategic Transaction within 6 months.","If Strategic Transaction within 3 months, Lehrer receives enhanced benefits as if termination during Change in Control.","Strategic Transaction defined broadly: merger, sale, reverse merger, or Sale Event under 2021 Stock Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-047925","json":"https://secwatch.observer/filing/0000950170-23-047925.json","markdown":"https://secwatch.observer/filing/0000950170-23-047925.md","text":"https://secwatch.observer/filing/0000950170-23-047925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023047925/0000950170-23-047925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023047925/grph-20230818.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:17:37.613421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a42f0ac1c","claim":"Josh Lehrer departed as President, Chief Executive Officer at LENZ Therapeutics, Inc..","evidence_excerpt":"effective as of August 21, 2023 (the “Termination Date”), Josh Lehrer, M.D., the former President, Chief Executive Officer and member of the Board of Directors of Graphite Bio, Inc. (the “Company”), separated from his employment and all officer and director positions with the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023047925/0000950170-23-047925-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"President, Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}